335 related articles for article (PubMed ID: 27502600)
1. The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.
Yin L; Ge Y; Yang H; Peng Q; Lu X; Zhang Y; Wang G
Clin Rheumatol; 2016 Nov; 35(11):2715-2721. PubMed ID: 27502600
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.
Yuan L; Yao L; Zhao L; Xia L; Shen H; Lu J
Clin Exp Rheumatol; 2013; 31(3):428-32. PubMed ID: 23485578
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.
Liu T; Hou Y; Dai TJ; Yan CZ
Chin Med J (Engl); 2017 Sep; 130(17):2101-2106. PubMed ID: 28836555
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-35 in idiopathic inflammatory myopathies.
Mann H; Kryštůfková O; Zámečník J; Háček J; Hulejová H; Filková M; Vencovský J; Šenolt L
Cytokine; 2021 Jan; 137():155350. PubMed ID: 33128920
[TBL] [Abstract][Full Text] [Related]
5. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
6. Surfactant protein D (SP-D) and systemic scleroderma (SSc).
Maeda M; Ichiki Y; Aoyama Y; Kitajima Y
J Dermatol; 2001 Sep; 28(9):467-74. PubMed ID: 11603386
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and specificity of Interleukin 29 in patients with rheumatoid arthritis and other rheumatic diseases.
da Rocha Junior LF; Branco Pinto Duarte AL; de Melo Rêgo MJB; de Almeida AR; de Melo Vilar K; de Lima HD; Tavares Dantas A; de Ataíde Mariz H; da Rocha Pitta I; da Rocha Pitta MG
Immunol Lett; 2020 Apr; 220():38-43. PubMed ID: 31954799
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.
Bentow C; Swart A; Wu J; Seaman A; Manfredi M; Infantino M; Benucci M; Lakos G; Mahler M
Clin Chim Acta; 2013 Sep; 424():141-7. PubMed ID: 23727029
[TBL] [Abstract][Full Text] [Related]
9. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies.
Notarnicola A; Lapadula G; Natuzzi D; Lundberg IE; Iannone F
Scand J Rheumatol; 2015 May; 44(3):224-8. PubMed ID: 25379698
[TBL] [Abstract][Full Text] [Related]
11. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.
Jiang Q; Li Y; Xia L; Shen H; Lu J
J Interferon Cytokine Res; 2019 Nov; 39(11):720-725. PubMed ID: 31274382
[TBL] [Abstract][Full Text] [Related]
13. Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.
Zhong Y; Bai W; Xie Q; Sun J; Tang H; Rao L
Int J Cardiovasc Imaging; 2018 May; 34(5):683-693. PubMed ID: 29168054
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis.
Silva MG; Oba-Shinjo SM; Marie SKN; Shinjo SK
Clin Exp Rheumatol; 2019; 37(4):656-662. PubMed ID: 30620283
[TBL] [Abstract][Full Text] [Related]
15. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
[TBL] [Abstract][Full Text] [Related]
16. Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies.
Xiao F; Tan JZ; Xu X; Zhu BL; Fang S; Wang XF
Clin Exp Rheumatol; 2015; 33(3):399-404. PubMed ID: 25936410
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis.
Muro Y; Nakashima R; Hosono Y; Sugiura K; Mimori T; Akiyama M
Arthritis Rheumatol; 2014 Dec; 66(12):3457-62. PubMed ID: 25186186
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
20. The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies.
Pleštilová L; Mann H; Andrés Cerezo L; Pecha O; Vencovský J; Šenolt L
Arthritis Res Ther; 2014 Oct; 16(5):468. PubMed ID: 25359220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
